110 related articles for article (PubMed ID: 741072)
1. [Contribution to the biochemical treatment of the Parkinson's disease (author's transl)].
Calatayud Maldonado V
Rev Esp Otoneurooftalmol Neurocir; 1978; 36(204):33-41. PubMed ID: 741072
[No Abstract] [Full Text] [Related]
2. [Pharmacokinetic and pharmacodynamic aspects of L-DOPA treatment and dopadecarboxilase inhibitors and dopaminergic antagonists in Parkinson's disease (author's transl)].
García de Yébenes J; Avila C; Bazán E; García E; Gervás J; Maseda C; Mena M; Muradas V; Ramos JA
Med Clin (Barc); 1982 Apr; 78(7):259-64. PubMed ID: 7087591
[No Abstract] [Full Text] [Related]
3. [CB 154 in the treatment of parkinson's disease--results of the association with L-DOPA + DDI (author's transl)].
Meco G; Casacchia M; Zamponi A; Agnoli A
Schweiz Rundsch Med Prax; 1976 May; 65(18):557-9. PubMed ID: 989900
[No Abstract] [Full Text] [Related]
4. [Effects of fusaric acid calcium on catecholamine metabolism and its clinical effects on essential hypertension].
Ozawa M; Nakajima Y; Suzuki K; Sato T; Takahashi E
Horumon To Rinsho; 1976 Jan; 24(1):79-86. PubMed ID: 942902
[No Abstract] [Full Text] [Related]
5. Effect of fusaric acid in Parkinson's disease.
Herskovits E; Figueroa Gacitua E
Medicina (B Aires); 1973; 33(1):51-8. PubMed ID: 4573120
[No Abstract] [Full Text] [Related]
6. [Mortality in Parkinson's disease and its modification by levodopa (author's transl)].
Schneider E; Fischer PA; Jacobi P; Kolb R
Fortschr Neurol Psychiatr; 1981 May; 49(5):187-92. PubMed ID: 7239405
[No Abstract] [Full Text] [Related]
7. [The association of L-DOPA and Ro 4-4602 in the treatment of Parkinson's disease (author's transl)].
Campanella G; Pennetta R
Riv Patol Nerv Ment; 1974 Oct; 95(5):673-5. PubMed ID: 4470267
[No Abstract] [Full Text] [Related]
8. [Improved therapeutic response to L-dopa in Parkinson's disease, when combined with bromocriptine (author's transl)].
Ulm G
Nervenarzt; 1981 Feb; 52(2):116-20. PubMed ID: 7219619
[No Abstract] [Full Text] [Related]
9. [Drug therapy in Parkinson's disease].
van Hilten JJ; Roos RA
Ned Tijdschr Geneeskd; 1999 Jan; 143(5):234-40. PubMed ID: 10086151
[TBL] [Abstract][Full Text] [Related]
10. [Treatment of pheochromocytoma with fusaric acid].
Shimpo S; Sakata K; Kawashimo K; Kanagi R; Omori Y
Horumon To Rinsho; 1976 Jun; 24(6):571-6. PubMed ID: 986906
[No Abstract] [Full Text] [Related]
11. [Proceedings: Case of pheochromocytoma].
Kawahara H; Kuzutani F; Mizuno S
Jpn Circ J; 1975 Jul; 39(7):871. PubMed ID: 1160060
[No Abstract] [Full Text] [Related]
12. [Treatment of Parkinson's disease with levodopa and a dopa decarboxylase inhibitor].
Londoõ R
Neurol Neurocir Psiquiatr; 1976; 17(4):293-300. PubMed ID: 1018729
[TBL] [Abstract][Full Text] [Related]
13. Suppression of craving and withdrawal in humans addicted to narcotics or amphetamines by administration of alpha-methyl-para-tyrosine (AMPT) and 5-butylpicolinic acid (fusaric acid) treatment of narcotic and amphetamine addiction in humans: preliminary report.
Pozuels J
Cleve Clin Q; 1976; 43(2):89-94. PubMed ID: 1277534
[No Abstract] [Full Text] [Related]
14. [Piribedil in the treatment of Parkinson disease (author's transl)].
Nardini M; Sciannandrone R; Fieschi C; De Simone G
Riv Patol Nerv Ment; 1975; 96(2):103-10. PubMed ID: 778998
[TBL] [Abstract][Full Text] [Related]
15. Decreased dopamine in the retinas of patients with Parkinson's disease.
Harnois C; Di Paolo T
Invest Ophthalmol Vis Sci; 1990 Nov; 31(11):2473-5. PubMed ID: 2243012
[TBL] [Abstract][Full Text] [Related]
16. Reevaluation of levodopa therapy for the treatment of advanced Parkinson's disease.
Yokochi M
Parkinsonism Relat Disord; 2009 Jan; 15 Suppl 1():S25-30. PubMed ID: 19131038
[TBL] [
